Back

Enalapril, eplerenone or their combination: finding the best paradigm to protect against Doxorubicin-Induced Cardiotoxicity

21 May 2016 (08:30 - 17:30)
Organised by:
Congress Presentation Part of: Poster Session 1 - Basic Science: Co-morbidities Cancer/Cardiotoxicity HFA Premium Access HEART FAILURE 2016

About the speaker

Photo
Professor Roger Hullin

University Hospital Centre Vaudois (CHUV), Lausanne (Switzerland)

4 More presentations in this session

Presentation thumbnail
Doctor N. Maurea (Naples, IT)
Abstract Slides
Presentation thumbnail
Doctor S. Nucera (Catanzaro, IT)
Abstract
Presentation thumbnail
Professor W. Kim (Seoul, KR)
Presentation thumbnail
Assistant Professor M. Trofenciuc (Arad, RO)
Abstract Slides

Access the full session

Session thumbnail
Poster Session 1 - Basic Science: Co-morbidities

The Event

Event poster

HEART FAILURE 2016

21 May 2016 08:30 CET
You may be interested in
thumbnail
Webinar
2022 ESC Guidelines on Cardio-Oncology: how to implement cancer treatment monitoring in daily practice
23 February 2023
thumbnail
Congress Presentation
Epirubicin promotes coronary endothelial senescence and dysfunction with induction of pro-inflammatory and pro-thrombotic responses: role of the AT1R/NADPH oxidases/SGLT2 pro-oxidant pathway
11 May 2026
thumbnail
Congress Presentation
Identifying a cardioprotective agent using human quadricellular cardiovascular organoids for modelling chemotherapy-induced cardiomyopathy.
22 May 2023
thumbnail
Congress Presentation
Systemic H-FABP, hs-cTnT, hs-CRP and Monocyte-to-Lymphocyte ratio were significantly reduced by sacubitril/valsartan in doxorubicin-treated preclinical models through NLRP3-mTOR-AKT pathways
1 September 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources